drugset

drugset / Trial / NCT01463631

A Study of LY3007113 in Participants With Advanced Cancer

NCT01463631 ↗

Phase 1 Completed 27 enrolled Eli Lilly and Company

NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the safety and tolerability of different doses of an experimental treatment in participants with advanced cancer.

Timeline

Start: 2011-12
Primary completion: 2013-12
Completion: 2013-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY3007113	Unknown	—	Oral

Indications